Moderna Inc
MRNAHealthcare|Biotechnology|USA
$48.77
-0.43 (-0.87%)
DCF (FCF)
$77.19
Tangible Book
$21.71
Clinical Trials (137)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07089706 A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations | COVID-19 | P4 | Recruiting | 832 | Open-label | mRNA-1283.251 Variant-containing Formulation |
| NCT06585241 A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | SARS-CoV-2 | P4 | Recruiting | 1,144 | Open-label | mRNA-1273 Variant-containing Formulation |
| NCT07279766 Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 | COVID-19 | P4 | Active | 285,000 | RCT, Open-label | mRNA-1273 (Moderna COVID-19 vaccine) |
| NCT07266558 A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 | P4 | Recruiting | 30,000 | RCT, Double-blind | mRNA-1273, mRNA-1283, Placebo |
| NCT06623422 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Carcinoma, Non-Small-Cell Lung | P3 | Recruiting | 680 | RCT, Double-blind | Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene |
| NCT06067230 A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | Respiratory Syncytial Virus | P3 | Active | 1,153 | RCT, Double-blind | mRNA-1345 |
| NCT07117487 A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age | Respiratory Syncytial Virus | P3 | Active | 507 | Open-label | mRNA-1345 |
| NCT07496450 A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | Influenza | P3 | Recruiting | 4,000 | RCT, Double-blind | mRNA-1018-H5, Placebo |
| NCT05933577 A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | Melanoma | P3 | Active | 1,089 | RCT, Double-blind | Intismeran autogene, Pembrolizumab |
| NCT06592794 A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis | Acute Gastroenteritis, Norovirus Acute Gastroenteritis | P3 | Active | 37,864 | RCT, Double-blind | mRNA-1403, Placebo |
| NCT06077760 A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | Non-small Cell Lung Cancer | P3 | Recruiting | 868 | RCT, Double-blind | Intismeran autogene, Pembrolizumab |
| NCT05668741 A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) | Cystic Fibrosis | P1P2 | Recruiting | 39 | Open-label | VX-522 mRNA therapy, IVA |
| NCT06735248 A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years | Multiple Sclerosis | P2 | Recruiting | 180 | RCT, Double-blind | mRNA-1195, Placebo |
| NCT06143046 A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers | Respiratory Syncytial Virus | P2 | Active | 360 | RCT, Double-blind | mRNA-1345, Placebo |
| NCT06833073 A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms | P2 | Recruiting | 308 | RCT, Open-label | Intismeran autogene, BCG |
| NCT06305767 A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | Bladder Cancer | P1P2 | Active | 230 | RCT, Double-blind | Pembrolizumab, Intismeran autogene, Enfortumab Vedotin |
| NCT05533697 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1P2 | Recruiting | 361 | Open-label | mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab |
| NCT05295433 An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705 | Methylmalonic Acidemia | P1P2 | Recruiting | 56 | Open-label | mRNA-3705 |
| NCT05683457 A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. | Cytomegalovirus Infection | P2 | Recruiting | 224 | RCT, Double-blind | mRNA-1647, Placebo |
| NCT05575492 A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | Cytomegalovirus | P1P2 | Active | 873 | RCT, Double-blind | mRNA-1647 |
| NCT07221474 A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | Squamous Non-small Cell Lung Cancer | P2 | Recruiting | 180 | RCT, Double-blind | V940, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel |
| NCT07116616 A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Multiple Myeloma | P1P2 | Recruiting | 166 | Open-label | mRNA-2808 |
| NCT05164094 A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | Epstein-Barr Virus Infection | P1P2 | Active | 867 | RCT, Double-blind | mRNA-1189, Placebo |
| NCT05992935 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | Norovirus Acute Gastroenteritis | P1P2 | Active | 1,407 | RCT, Double-blind | mRNA-1403, mRNA-1405, Placebo |
| NCT05095727 A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) | Glycogen Storage Disease | P1P2 | Active | 15 | Open-label | mRNA-3745 |
| NCT03897881 An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | Melanoma | P2 | Active | 267 | RCT, Open-label | mRNA-4157, Pembrolizumab |
| NCT06307431 A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). | Renal Cell Carcinoma | P2 | Active | 272 | RCT, Double-blind | Intismeran autogene, Pembrolizumab, Placebo |
| NCT04899310 A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia | Methylmalonic Acidemia | P1P2 | Active | 74 | RCT, Double-blind | mRNA-3705, Placebo |
| NCT05701800 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age | Herpes Zoster | P1P2 | Active | 659 | RCT, Double-blind | mRNA-1468, Placebo, Shingrix |
| NCT04159103 Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia | Propionic Acidemia | P1P2 | Recruiting | 77 | Open-label | mRNA-3927 |
| NCT05130437 A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study | Propionic Acidemia | P1P2 | Recruiting | 50 | Open-label | mRNA-3927 |
| NCT07478952 A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age | Epstein-Barr Virus | P1 | Recruiting | 120 | RCT, Open-label | mRNA-1189 |
| NCT05001373 A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) | Hiv | P1 | Active | 56 | RCT, Open-label | Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine |
| NCT06946225 ACTengine® IMA203 Combined With mRNA-4203 | Cutaneous Melanoma, Synovial Sarcoma | P1 | Recruiting | 15 | Open-label | IMA203, mRNA-4203 |
| NCT06880549 A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | Advanced Solid Tumors | P1 | Active | 57 | Open-label | mRNA-4106, Nivolumab/Relatlimab |
| NCT03313778 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors | Solid Tumors | P1 | Active | 161 | Open-label | mRNA-4157, Pembrolizumab, SoC Treatment |
| NCT05831111 A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | Epstein-Barr Virus Infection | P1 | Active | 482 | RCT, Double-blind | mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195 |
| NCT05743881 A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | Respiratory Syncytial Virus, Human Metapneumovirus | P1 | Active | 186 | RCT, Double-blind | mRNA-1345, mRNA-1365, Placebo, Nimenrix |
| NCT06655870 A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants | Healthy Participants | P1 | Active | 52 | RCT, Open-label | mRNA-0184 |
| NCT06694753 Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa. | HIV Infections | P1 | Recruiting | 96 | RCT, Double-blind | mRNA-1645-eODGT8, mRNA-1645-CoreG28v2, mRNA-1645-N332GT5, Placebo |
| NCT02872025 Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) | Carcinoma, Intraductal, Noninfiltrating | Early P1 | Active | 42 | Open-label | Pembrolizumab, Intralesional mRNA 2752 |
| NCT06522880 Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study | Cytomegalovirus Infections | Recruiting | 100 | — | — | |
| NCT06333704 Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection. | SARS-CoV-2 | Recruiting | 4,206 | — | SPIKEVAX Bivalent, SPIKEVAX X | |
| NCT06189053 A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX) | Myocarditis | Active | 1,500 | — | — | |
| NCT05769621 A Retrospective Study to Characterize Participants With Propionic Acidemia | Propionic Acidemia | Recruiting | 60 | — | — | |
| NCT05831787 COVID19 OutcomeS in Myeloma and the Impact of VaCcines | Multiple Myeloma | Active | 200 | — | — | |
| NCT06634797 A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age | Healthy Volunteers | P4 | Completed | 1,000 | RCT, Double-blind | mRNA-1273.712, Placebo |
| NCT04805125 Immunocompromised Swiss Cohorts Based Trial Platform | Immunocompromised Patients | P3 | Completed | 610 | RCT, Open-label | Moderna COVID-19 Vaccine, mRNA-1273 (100 μg), Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®) |
| NCT06602024 A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age | Seasonal Influenza | P3 | Completed | 40,817 | RCT, Double-blind | mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra |
| NCT04470427 A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 | SARS-CoV-2 | P3 | Completed | 30,415 | RCT, Double-blind | mRNA-1273, Placebo |
| NCT05815498 A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 | COVID-19 | P3 | Completed | 14,246 | RCT, Double-blind | mRNA-1283.222, mRNA-1273.222, mRNA-1283.815, mRNA-1273.815 |
| NCT04860297 A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants | SARS-CoV-2 | P3 | Completed | 234 | Open-label | mRNA-1273 |
| NCT05415462 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | Seasonal Influenza | P3 | Completed | 6,102 | RCT, Double-blind | mRNA-1010, Fluarix Tetra |
| NCT06097273 A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age | SARS-CoV-2, Influenza | P3 | Completed | 8,061 | RCT, Double-blind | mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine |
| NCT05127434 A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age | Respiratory Syncytial Virus | P2P3 | Completed | 36,814 | RCT, Double-blind | Placebo, mRNA-1345 |
| NCT04796896 A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age | SARS-CoV-2 | P2P3 | Completed | 11,942 | RCT, Double-blind | mRNA-1273, Placebo, mRNA-1273.214 |
| NCT06694389 Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age | COVID-19, Influenza | P3 | Completed | 2,457 | RCT, Double-blind | mRNA-1083, Licensed Influenza Vaccine, SARS-CoV-2 Vaccine |
| NCT04927065 A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants | SARS-CoV-2 | P2P3 | Completed | 5,161 | Open-label | mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, mRNA-1273.231 |
| NCT06060457 A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age | Respiratory Syncytial Virus | P3 | Completed | 1,900 | RCT, Double-blind | Placebo, mRNA-1345, Fluzone HD |
| NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older | Seasonal Influenza | P3 | Completed | 22,502 | RCT, Double-blind | mRNA-1010, Fluarix Quadrivalent |
| NCT04649151 A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 | SARS-CoV-2 | P2P3 | Completed | 4,328 | RCT, Double-blind | mRNA-1273, Placebo, mRNA-1273.222 |
| NCT05330975 A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age | Respiratory Syncytial Virus | P3 | Completed | 3,317 | RCT, Double-blind | Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214 |
| NCT06295809 A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) | Carcinoma, Squamous Cell, Skin Neoplasms | P2P3 | Completed | 46 | RCT, Single-blind | Pembrolizumab, Intismeran autogene |
| NCT06354998 A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults | SARS-CoV-2 | P3 | Completed | 217 | RCT, Double-blind | Investigational mRNA-1273.815, Licensed Spikevax Vaccine |
| NCT05249829 A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 | SARS-CoV-2 | P2P3 | Completed | 3,548 | RCT, Double-blind | mRNA-1273.529, mRNA-1273, mRNA-1273.214 |
| NCT05827978 Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | Seasonal Influenza | P3 | Completed | 8,411 | RCT, Double-blind | mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine |
| NCT05085366 A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | Cytomegalovirus Infection | P3 | Terminated | 7,454 | RCT, Double-blind | mRNA-1647, Placebo |
| NCT05436834 A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age | SARS-CoV-2 | P3 | Completed | 1,807 | Open-label | mRNA-1273.214, mRNA-1273.815 |
| NCT04232280 Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults | Cytomegalovirus Infection | P2 | Completed | 315 | RCT, Double-blind | mRNA-1647 |
| NCT05868382 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults | Influenza | P2 | Completed | 270 | RCT, Double-blind | mRNA-1010, mRNA-1010.4, mRNA-1010.6 |
| NCT06864143 A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age | Influenza, SARS-CoV-2 | P2 | Completed | 1,320 | RCT, Double-blind | mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B |
| NCT05584202 Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | SARS-CoV-2 | P2 | Terminated | 68 | RCT, Double-blind | mRNA-1273.214 |
| NCT06097299 A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | Respiratory Syncytial Virus | P2 | Completed | 346 | RCT, Double-blind | mRNA-1345, Placebo |
| NCT05827068 A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults | Seasonal Influenza | P1P2 | Completed | 698 | RCT, Open-label | mRNA-1011.1, mRNA-1011.2, mRNA-1012.1, mRNA-1010, mRNA-1010.2, mRNA-1010.3 |
| NCT05827926 A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | SARS-CoV-2, Influenza | P1P2 | Completed | 1,758 | RCT, Double-blind | Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1, Investigational COVID-19 Vaccine 1, COVID-19 Vaccine 1, Investigational Influenza Vaccine 2, Influenza Vaccine 2, mRNA-1083, Investigational COVID-19 Vaccine 2, COVID-19 Vaccine 2 |
| NCT05280158 High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients | Lung Transplant Recipient, SARS-CoV-2 | P1P2 | Terminated | 19 | RCT, Open-label | mRNA-1273 (Moderna COVID-19 vaccine) |
| NCT06133010 A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients | Cytomegalovirus Infection | P2 | Withdrawn | — | RCT, Double-blind | mRNA-1647, Placebo |
| NCT04405076 Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | SARS-CoV-2 | P2 | Completed | 660 | RCT, Double-blind | Biological: mRNA-1273, Placebo, mRNA-1273.351 |
| NCT05375838 A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old | SARS-CoV-2, Influenza | P1P2 | Completed | 550 | RCT, Double-blind | mRNA-1073, mRNA-1010, mRNA-1273, Placebo |
| NCT06033261 A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes | Genital Herpes | P1P2 | Completed | 365 | RCT, Double-blind | mRNA-1608, BEXSERO |
| NCT05995275 A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age | Smallpox, Mpox | P1P2 | Completed | 351 | RCT, Double-blind | mRNA-1769 |
| NCT03810690 Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia | Methylmalonic Acidemia (MMA), Metabolism, Inborn Errors | P1P2 | Withdrawn | — | Open-label | mRNA-3704 |
| NCT06508320 A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) | Influenza, SARS-CoV-2 | P2 | Completed | 932 | RCT, Double-blind | mRNA-1083 |
| NCT05137236 A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters | SARS-CoV-2 | P2 | Completed | 540 | RCT, Double-blind | mRNA-1283, mRNA-1283.211, mRNA-1273, mRNA-1283.529 |
| NCT05975099 A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | Lyme Disease | P1P2 | Completed | 807 | RCT, Double-blind | mRNA-1975, mRNA-1982, Placebo |
| NCT04975893 A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | Cytomegalovirus Infection | P2 | Completed | 135 | Open-label | mRNA-1647 |
| NCT05333289 A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults | Seasonal Influenza | P1P2 | Completed | 572 | RCT, Double-blind | mRNA-1030, mRNA-1020, mRNA-1010, Active Comparator |
| NCT05972174 A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | Influenza | P1P2 | Completed | 1,504 | RCT, Double-blind | mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only, mRNA-1018 for H7 Only, mRNA-1018 for H5 Only-CG |
| NCT05383560 Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults | COVID-19 Pandemic, Immunogenicity | P2 | Completed | 179 | RCT, Double-blind | mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, Placebo, MRNA-1273.222 Vaccine |
| NCT04956575 A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults | Seasonal Influenza | P1P2 | Completed | 885 | RCT, Double-blind | mRNA-1010, Placebo, Active Comparator |
| NCT03323398 Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer | P1P2 | Terminated | 79 | Open-label | mRNA-2416, Durvalumab |
| NCT05606965 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults | Influenza | P2 | Completed | 172 | RCT, Open-label | mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine, mRNA-1345, mRNA-1045 |
| NCT04917861 A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | Zika Virus | P2 | Completed | 808 | RCT, Double-blind | mRNA-1893, Placebo |
| NCT06147856 A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria | Phenylketonuria | P1P2 | Withdrawn | — | Open-label | mRNA-3210 |
| NCT05585632 A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old | SARS-CoV-2, Influenza | P1 | Completed | 392 | RCT, Double-blind | mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230 |
| NCT05397223 A Study of Modified mRNA Vaccines in Healthy Adults | SARS-CoV-2, Seasonal Influenza | P1 | Completed | 308 | RCT, Open-label | mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647 |
| NCT04813796 A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 | SARS-CoV-2 | P1 | Completed | 104 | RCT, Double-blind | mRNA-1283, mRNA-1273, Placebo |
| NCT06243770 Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants | Healthy Participants | P1 | Completed | 44 | RCT, Open-label | mRNA-0184 |
| NCT04528719 A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | Respiratory Syncytial Virus | P1 | Completed | 651 | RCT, Double-blind | mRNA-1345, Placebo |
| NCT04916431 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults | Healthy Volunteers | P1 | Completed | 18 | Open-label | mRNA-6231 |
| NCT04064905 Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults | Zika Virus | P1 | Completed | 120 | RCT, Double-blind | mRNA-1893 |
| NCT03014089 Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects | Zika Virus | P1 | Completed | 90 | RCT, Double-blind | mRNA-1325 |
| NCT03739931 Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma | P1 | Completed | 134 | Open-label | mRNA-2752, Durvalumab |
| NCT04283461 Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) | COVID-19, COVID-19 Immunisation | P1 | Completed | 120 | Open-label | mRNA-1273 |
| NCT03076385 Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects | Influenza | P1 | Completed | 201 | RCT, Double-blind | VAL-506440 |
| NCT03325075 Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants | Chikungunya Virus | P1 | Completed | 60 | RCT, Double-blind | VAL-181388 |
| NCT03829384 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults | Prevention of Chikungunya Virus Infection | P1 | Completed | 39 | RCT, Double-blind | mRNA-1944 |
| NCT03345043 Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects | Influenza | P1 | Completed | 156 | RCT, Double-blind | VAL-339851 |
| NCT05918250 mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Relapsed or Refractory Multiple Myeloma | P1 | Withdrawn | — | Open-label | mRNA-2736 |
| NCT04785144 Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults | COVID-19, COVID-19 Immunisation | P1 | Completed | 135 | RCT, Open-label | mRNA-1273, mRNA-1273.351 |
| NCT05398796 Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults | Nipah Virus Infection | P1 | Completed | 40 | Open-label | mRNA -1215 |
| NCT05105048 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 | Cytomegalovirus Infection | P1 | Completed | 9 | RCT, Double-blind | mRNA-1647, Placebo |
| NCT04144348 Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure | Human Metapneumovirus and Human Parainfluenza Infection | P1 | Completed | 51 | RCT, Double-blind | mRNA-1653, Placebo |
| NCT03392389 Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults | Human Metapneumovirus and Human Parainfluenza Infection | P1 | Completed | 124 | RCT, Double-blind | mRNA-1653 |
| NCT03948763 A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | Neoplasms, Carcinoma, Non-Small-Cell Lung | P1 | Terminated | 70 | Open-label | V941, Pembrolizumab |
| NCT05659264 A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure | Chronic Heart Failure | P1 | Completed | 48 | RCT, Single-blind | mRNA-0184, Placebo |
| NCT03382405 Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults | Cytomegalovirus Infection | P1 | Completed | 181 | RCT, Double-blind | mRNA-1647, mRNA-1443 |
| NCT05414786 A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) | HIV-1-infection | P1 | Unknown | 18 | Open-label | eOD-GT8 60mer mRNA Vaccine (100µg) |
| NCT05366322 A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults | SARS-CoV-2 | Completed | 124,879 | — | — | |
| NCT05440318 Use of Wearable Digital Sensors After mRNA Vaccination in Adults | Healthy Participants | Completed | 62 | — | — | |
| NCT05054218 COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients | Covid19, SARS-CoV2 Infection | Completed | 336 | — | mRNA-1273 | |
| NCT04958304 Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study | SARS-CoV-2 | Terminated | 20 | — | — | |
| NCT06130345 Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran | SARS-CoV-2 | Completed | 15,196,685 | — | SPIKEVAX | |
| NCT05894525 Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine | SARS-CoV-2 | Completed | 8,844 | — | — | |
| NCT04941144 Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination | Coronavirus Disease (COVID-19) | Completed | 8,538 | — | COVID-19 Vaccine | |
| NCT06646406 Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate | COVID-19 Immunisation, Influenza Vaccine | N/A | Completed | 114,165 | RCT, Double-blind | — |
| NCT06369272 Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy | Maternal Outcomes, Infant Outcomes | Completed | 1,192 | — | — | |
| NCT05572658 Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study | Respiratory Syncytial Virus | Completed | 10,994 | — | mRNA-1345, Placebo | |
| NCT05894499 Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19 | SARS-CoV-2 | Completed | 13,309 | — | — | |
| NCT03484767 "The MaP Study": Mapping the Patient Journey in MMA and PA | Methylmalonic Acidemia, Propionic Acidemia | Completed | 97 | — | — | |
| NCT05933304 A Study of the Effectiveness of Moderna COVID-19 Vaccine | SARS-CoV-2, COVID-19 | Completed | 927,004 | — | — | |
| NCT05765578 An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5) | COVID-19 | Completed | 1,713 | — | Moderna COVID-19 Vaccine, Moderna mRNA1273.222 Booster, Pfizer COVID-19 Vaccine, Moderna 2023 Updated COVID-19 vaccine (XBB.1.5), Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5) | |
| NCT05894590 Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19 | SARS-CoV-2 | Completed | 13,680 | — | — | |
| NCT05367908 A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind | SARS-CoV-2 | Completed | 1,501 | — | — | |
| NCT04958954 Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States | SARS-CoV-2 | Completed | 50,000,000 | — | — | |
| NCT05794412 Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study | SARS-CoV-2 Infection, Influenza Viral Infections | Completed | 320 | — | — | |
| NCT06113692 A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine | Myocarditis, Pericarditis | Completed | 1,169 | — | mRNA-1273 |